$CUE
Cue Biopharma Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020052490 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $700.0K $984.0K $1.055M
YoY Change -28.86% 119.15% 513.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.290M $2.750M $3.390M
YoY Change 19.64% -4.84% 52.7%
% of Gross Profit
Research & Development $7.517M $5.302M $6.867M
YoY Change 41.78% -48.59% 26.84%
% of Gross Profit
Depreciation & Amortization $199.0K $194.0K $205.0K
YoY Change 2.58% -0.51% 5.13%
% of Gross Profit
Operating Expenses $10.84M $8.078M $10.29M
YoY Change 34.13% -21.67% 34.56%
Operating Profit -$10.13M -$7.094M
YoY Change 42.81% -44.4%
Interest Expense $123.0K $99.00K $96.00K
YoY Change 24.24% -2.94% -43.53%
% of Operating Profit
Other Income/Expense, Net $100.0K $104.0K $122.0K
YoY Change -3.85% -48.0% -29.07%
Pretax Income -$10.03M -$6.990M -$9.109M
YoY Change 43.51% -44.34% 24.78%
Income Tax $0.00 $413.0K
% Of Pretax Income
Net Earnings -$10.03M -$6.990M -$9.522M
YoY Change 43.51% -44.31% 30.44%
Net Earnings / Revenue -1433.0% -710.37% -902.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$338.3K -$311.4K -$457.3K
COMMON SHARES
Basic Shares Outstanding 20.78M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.95M $31.53M $28.26M
YoY Change 191.65% -19.57% -38.31%
Cash & Equivalents $71.88M $31.53M $24.26M
Short-Term Investments $20.07M $0.00 $3.995M
Other Short-Term Assets $1.300M $1.000M $1.000M
YoY Change 30.0% -28.57% -71.43%
Inventory
Prepaid Expenses
Receivables $500.0K $610.0K $522.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $93.60M $32.99M $29.87M
YoY Change 183.72% -18.74% -39.35%
LONG-TERM ASSETS
Property, Plant & Equipment $1.739M $2.031M $2.208M
YoY Change -14.38% -29.97% -20.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.400M $793.0K $838.0K
YoY Change 328.75% -11.89% -6.89%
Total Long-Term Assets $13.00M $12.22M $11.89M
YoY Change 6.39% 206.86% 207.66%
TOTAL ASSETS
Total Short-Term Assets $93.60M $32.99M $29.87M
Total Long-Term Assets $13.00M $12.22M $11.89M
Total Assets $106.6M $45.21M $41.76M
YoY Change 135.79% 1.41% -21.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $1.178M $2.289M
YoY Change -6.62% 18.15% 319.23%
Accrued Expenses $7.200M $1.555M $2.580M
YoY Change 363.02% -31.44% 129.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.20M $10.39M $11.27M
YoY Change 36.64% 126.65% 280.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.800M $7.800M $10.20M
YoY Change -38.46%
Total Long-Term Liabilities $4.800M $7.800M $10.20M
YoY Change -38.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.20M $10.39M $11.27M
Total Long-Term Liabilities $4.800M $7.800M $10.20M
Total Liabilities $19.10M $18.19M $21.48M
YoY Change 5.02% 251.24% 453.19%
SHAREHOLDERS EQUITY
Retained Earnings -$99.58M -$92.59M
YoY Change 65.48% 94.4%
Common Stock $126.6M $112.9M
YoY Change 27.11% 16.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.55M $27.02M $20.28M
YoY Change
Total Liabilities & Shareholders Equity $106.6M $45.21M $41.76M
YoY Change 135.79% 1.41% -21.38%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$10.03M -$6.990M -$9.522M
YoY Change 43.51% -44.31% 30.44%
Depreciation, Depletion And Amortization $199.0K $194.0K $205.0K
YoY Change 2.58% -0.51% 5.13%
Cash From Operating Activities -$7.690M -$9.210M -$6.670M
YoY Change -16.5% 46.42% 3.25%
INVESTING ACTIVITIES
Capital Expenditures -$350.0K -$20.00K $0.00
YoY Change 1650.0% -93.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.000M $4.000M $5.130M
YoY Change 25.0% -117.16%
Cash From Investing Activities $4.650M $3.980M $5.130M
YoY Change 16.83% -116.86% -775.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.01M 12.30M 3.740M
YoY Change 22.03% 122900.0%
NET CHANGE
Cash From Operating Activities -7.690M -9.210M -6.670M
Cash From Investing Activities 4.650M 3.980M 5.130M
Cash From Financing Activities 15.01M 12.30M 3.740M
Net Change In Cash 11.97M 7.070M 2.200M
YoY Change 69.31% -123.65% -130.47%
FREE CASH FLOW
Cash From Operating Activities -$7.690M -$9.210M -$6.670M
Capital Expenditures -$350.0K -$20.00K $0.00
Free Cash Flow -$7.340M -$9.190M -$6.670M
YoY Change -20.13% 53.42% 17.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2680
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.934
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0176
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.820
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0178
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.996
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0259
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.940
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
15120000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
755000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
860000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
61025000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1847000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5337000
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2572000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
674000
CY2019Q4 us-gaap Assets
Assets
71605000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
883000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2227000
CY2019Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
4097000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4448000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11655000
CY2019Q4 cue Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
4018000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1348000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2409000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9640000
us-gaap Operating Expenses
OperatingExpenses
30163000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27754000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
309000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
386000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
386000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10031000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6990000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33682000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27368000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
10835000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-74000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
100000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44290000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34068000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
460000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2679000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11205000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25542000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6990000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
80154000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
27022000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54584000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8199000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1799000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
123000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
99000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3318000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2776000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
8078000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10131000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
984000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7517000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5302000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7094000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26562178
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71605000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26562178
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163068000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54584000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20523000
us-gaap Operating Expenses
OperatingExpenses
36747000
CY2019Q4 us-gaap Liabilities
Liabilities
17021000
us-gaap Net Income Loss
NetIncomeLoss
-33682000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
355000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27439000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25495000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-5000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5436000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1799000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
111000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16296000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10529000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21000000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31529000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4525000
cue Number Of Tranches
NumberOfTranches
2
us-gaap Net Income Loss
NetIncomeLoss
-27782000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
83000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
82000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
11000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6990000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33600000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27771000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22450071
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28151361
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21334195
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9948000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
33972000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
413000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10031000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6990000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29650909
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
87553000
us-gaap Profit Loss
ProfitLoss
-33682000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
20280000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11937000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1440000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
27022000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14329000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2500000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
719000
CY2020Q3 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
35000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-83000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10031000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
87553000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15652000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4525000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
644000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
11000
us-gaap Net Income Loss
NetIncomeLoss
-27782000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56682000
us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
111000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
82000
us-gaap Net Income Loss
NetIncomeLoss
-33682000
us-gaap Profit Loss
ProfitLoss
-27782000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
804000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
605000
us-gaap Share Based Compensation
ShareBasedCompensation
8199000
us-gaap Share Based Compensation
ShareBasedCompensation
4525000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
-2539000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
3036000
us-gaap Other Noncash Income
OtherNoncashIncome
68000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
77000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-54000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-298000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
610000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
443000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-354000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
250000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-1576000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2406000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3029000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
225000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-857000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
355000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-233000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-945000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
1222000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24359000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
127000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-18501000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
9949000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18592000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56682000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15652000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
644000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58370000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44440000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71879000
us-gaap Income Taxes Paid
IncomeTaxesPaid
413000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
91803000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 outbreak, which the World Health Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to issue “stay-at-home” or similar orders, and enact restrictions on the performance of “non-essential” services, public gatherings and travel. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent of its impact on worldwide macroeconomic conditions, the speed of the anticipated recovery, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic as of September 30, 2020 and through the date of the filing of this Quarterly Report on Form 10-Q. The accounting matters assessed included, but were not limited to, estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets and intangibles. The Company’s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the Company’s efforts, the ultimate impact of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandemic </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandemic </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will negatively impact its financial results or liquidity.</span></p>
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
150000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
150000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6323891
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5881526
CY2020Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
37813000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20074000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39304000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15120000
CY2020Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
57887000
CY2020Q3 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54424000
CY2019Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20002000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
72000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20074000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15130000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15120000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20074000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
15120000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2500000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1439000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8199000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
94375
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4361000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3873000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2622000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2026000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1739000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1847000
us-gaap Depreciation
Depreciation
596000
us-gaap Depreciation
Depreciation
605000
cue Amortization Of Trademark
AmortizationOfTrademark
9000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
199000
CY2020Q3 us-gaap Depreciation
Depreciation
199000
CY2019Q3 us-gaap Depreciation
Depreciation
194000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2020Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4793253
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
964300
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.34
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
377747
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
181219
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.71
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5198587
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.05
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2792928
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.91
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18104000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22908000
CY2020Q3 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
15.05
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
7.83
CY2020Q1 cue Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod
P12M
CY2020Q2 cue Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod
P36M
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1189827
cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
278179
cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
49679
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
861969
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1173000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5080000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2408000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8661000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
459000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8202000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1212000
CY2019Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1137000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3372000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3411000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1169000
us-gaap Operating Lease Payments
OperatingLeasePayments
3372000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1212000
us-gaap Operating Lease Cost
OperatingLeaseCost
3372000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M15D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M15D
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7876000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8202000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1212000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3372000

Files In Submission

Name View Source Status
0001564590-20-052490-index-headers.html Edgar Link pending
0001564590-20-052490-index.html Edgar Link pending
0001564590-20-052490.txt Edgar Link pending
0001564590-20-052490-xbrl.zip Edgar Link pending
cue-10q_20200930.htm Edgar Link pending
cue-10q_20200930_htm.xml Edgar Link completed
cue-20200930.xsd Edgar Link pending
cue-20200930_cal.xml Edgar Link unprocessable
cue-20200930_def.xml Edgar Link unprocessable
cue-20200930_lab.xml Edgar Link unprocessable
cue-20200930_pre.xml Edgar Link unprocessable
cue-ex102_176.htm Edgar Link pending
cue-ex311_6.htm Edgar Link pending
cue-ex312_7.htm Edgar Link pending
cue-ex31_253.htm Edgar Link pending
cue-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g1xw3xndha40000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending